MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease 

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC), MedicAlert Foundation, and Sickle Cell Disease Association of America announced a three-year partnership on March 19, 2026 to speed emergency department care for people with sickle cell disease by providing MedicAlert Smart Medical ID Cards linked to physician-approved digital care plans.

The program enables ED clinicians to scan a card QR code to access pain plans, hematologist contacts, medications, allergies, and other critical health information to reduce delays during pain crises.

News Market Reaction – FULC

+1.73%

+1.73% Session close to close

In the Mar 19 session, FULC gained 1.73%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Fulcrum’s focus on the broader care journey for sickle cell disease by ...

Analysis

This announcement highlights Fulcrum’s focus on the broader care journey for sickle cell disease by partnering with MedicAlert and SCDAA to speed emergency department access to patient-specific care plans. Unlike prior updates that detailed Phase 1b PIONEER efficacy and a $352.3M cash position, this news centers on care coordination for roughly 100,000 affected individuals in the U.S. Investors may watch how such collaborations complement ongoing clinical plans and regulatory milestones for pociredir.

Key Figures

Collaboration duration: Three-year collaboration SCD population: 100,000 people Program launch year: 2023

3 metrics

Collaboration duration Three-year collaboration Length of partnership to enhance sickle cell crisis care

SCD population 100,000 people Estimated number of people with sickle cell disease in the U.S.

Program launch year 2023 Original launch year of MedicAlert–SCDAA program

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 06	Inducement option grant	Neutral	-2.8%	Stock options granted to new employee under inducement plan.
Mar 03	Conference participation	Neutral	+0.8%	Company scheduled to present at Leerink Partners healthcare conference.
Feb 24	Earnings & SCD data	Positive	-21.2%	Positive Phase 1b SCD data and strong year-end cash position reported.
Feb 24	Positive trial update	Positive	-21.2%	Detailed 12-week Phase 1b PIONEER results for pociredir in SCD.
Feb 17	Data presentation plan	Neutral	+0.3%	Announcement of upcoming presentation of 12-week PIONEER data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong positive clinical and earnings updates for sickle cell disease coinciding with sharp negative price reactions, while neutral corporate or conference news has seen modest moves.

Recent Company History

Over the last month, Fulcrum has focused on advancing pociredir for sickle cell disease and aligning leadership incentives. On Feb 24, 2026, it reported positive Phase 1b PIONEER data and strong cash of $352.3M, yet shares fell about 21% on both the earnings and detailed trial updates. Earlier, it flagged upcoming data on Feb 17 and conference participation in early March with minimal price impact. The new care-coordination partnership for sickle cell builds on this patient-focused strategy rather than adding new efficacy or financial data.

Key Terms

sickle cell disease, emergency department, hematologist, qr code, +1 more

5 terms

sickle cell disease medical

"people living with sickle cell disease (SCD) through rapid access to patient-specific"

Sickle cell disease is an inherited blood disorder where red blood cells become rigid and crescent-shaped, causing them to clump and block small blood vessels; this leads to recurrent pain, organ damage and higher risk of infection. For investors it matters because the condition drives ongoing healthcare costs, creates demand for new drugs, gene therapies and diagnostics, affects payer and hospital economics, and can influence workforce productivity and insurance liabilities—making progress or setbacks in treatments a market-moving factor.

emergency department medical

"expedite emergency department (ED) care for people living with sickle cell disease"

A hospital’s emergency department is the 24/7 clinical unit that evaluates and treats people with urgent or life‑threatening conditions, acting like the hospital’s front door for immediate care. For investors, its volume and performance signal demand for healthcare services, affect hospital revenue and cost patterns, and influence regulatory and reimbursement risks—similar to how customer foot traffic informs the health of a retail business.

hematologist medical

"including the patient’s physician-approved sickle cell pain plan, hematologist contact information"

A hematologist is a medical doctor who specializes in diagnosing and treating blood-related conditions, such as anemia, blood cancers, and clotting disorders. Their work is important because blood health can impact overall well-being and can influence the success of treatments for various diseases. For investors, understanding hematologists helps clarify advancements in medical research and therapies that may affect healthcare companies and markets.

qr code technical

"When the card’s QR code is scanned by ED personnel, clinicians can quickly"

A QR code is a square, two‑dimensional barcode that stores information such as a website link, payment details, or product data and can be read instantly by a smartphone camera. For investors it matters because companies use QR codes to drive customer engagement, speed payments, track inventory, or provide instant access to reports and disclosures—similar to a digital shortcut that connects physical items or ads directly to online actions that can affect sales, costs, and transparency.

digital health profile technical

"Smart Medical ID Card linked to a secure digital health profile. When the card’s"

A digital health profile is an organized collection of a person’s health information and the connected tools that gather it—such as wearable data, medical records, symptom logs and app settings—stored and shared electronically. For investors it matters because these profiles represent valuable data assets and product hooks that can drive user engagement, recurring revenue and partnerships, while also bringing privacy, security and regulatory risks that affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (Nasdaq: FULC), a leader in advancing therapies for underserved patient populations, today announced a new partnership designed to help streamline and expedite emergency department (ED) care for people living with sickle cell disease (SCD) through rapid access to patient-specific care plans.

Individuals living with SCD, an inherited blood disorder, frequently seek care in EDs during acute pain crises. In these urgent care situations, immediate access to health information is a vital step in helping clinicians deliver the timely, targeted care that people with SCD need.

“Too often, individuals living with SCD face barriers to receiving appropriate and compassionate care quickly during a pain crisis in the emergency department,” said Regina Hartfield, President and CEO, SCDAA. “This partnership represents an important step forward in this program, originally launched in 2023 between MedicAlert and SCDAA. Fulcrum’s commitment will enable us to broaden our reach into SCDAA’s membership and to the SCD community and will empower so many more individuals living with SCD with a trusted way to effectively share their care and/or pain plans and medical information with emergency clinicians, helping ensure their voices and needs are recognized when they seek care.”

Through this program, participants receive a MedicAlert Smart Medical ID Card linked to a secure digital health profile. When the card’s QR code is scanned by ED personnel, clinicians can quickly access essential medical information including the patient’s physician-approved sickle cell pain plan, hematologist contact information, medications, allergies, and other vital health data.

“When a person with SCD comes to the ED during a pain crisis, lack of access to patient-specific care plans can result in prolonged suffering,” said Karen Cassel, President and CEO, MedicAlert Foundation “That’s where our emergency response system comes in. It’s designed to help address this pain point by enabling faster clinical decision-making.”

SCD is long overdue for improvements in care coordination to help ease the burden of this painful and devastating disease that affects 100,000 people in the U.S., many of whom have been left behind amid the shortcomings in the current landscape. The often unmet needs of patients necessitate urgency to adopt new and unique collaborations that help close the gap in their experiences.

“At Fulcrum, we are committed not only to developing innovative therapies, but also to advancing solutions that improve the entire care journey for people living with SCD,” said Alex Sapir, CEO, Fulcrum Therapeutics. “Through this partnership, we hope to help solve some of the most pervasive challenges people living with SCD face and reduce delays in care when minutes matter most.”

For those living with SCD who are interested in learning more or securing a MedicAlert Smart Medical ID Card through this partnership, please visit https://www.medicalert.org/sicklecellpilot/.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com 

About the Sickle Cell Disease Association of America

The Sickle Cell Disease Association of America, Inc. (SCDAA) advocates for people affected by sickle cell conditions and empowers community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure. The association and its more than 50 member organizations support sickle cell research, public and professional health education and community services. (www.sicklecelldisease.org)

About MedicAlert Foundation

The MedicAlert Foundation is a global nonprofit organization dedicated to protecting and saving lives by providing trusted medical identification and emergency health information services. MedicAlert’s secure digital health profiles and medical ID products ensure that critical health information is available to first responders and healthcare providers during medical emergencies. For more information, visit https://www.medicalert.org/

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What is the Fulcrum (FULC) partnership announced March 19, 2026 with MedicAlert and SCDAA?

It is a three-year collaboration to expedite ED care for people with sickle cell disease by providing MedicAlert Smart Medical ID Cards. According to Fulcrum, the program links QR-coded cards to secure, physician-approved digital profiles that share pain plans and contact information with ED clinicians.

How does the MedicAlert Smart Medical ID Card help patients with sickle cell disease in the emergency department?

The card gives ED staff rapid access to patient-specific care plans, reducing delays in treatment during pain crises. According to MedicAlert, scanning the QR code reveals physician-approved pain plans, hematologist contacts, medications, allergies, and other vital data for faster clinical decisions.

Who is eligible to enroll in the MedicAlert program through Fulcrum and SCDAA and how can they sign up?

Individuals living with sickle cell disease and SCDAA members are eligible to participate and obtain a MedicAlert Smart Medical ID Card. According to the organizations, interested people can learn more and sign up via the MedicAlert sickle cell pilot webpage provided by the partners.

What is the expected timeline and duration of Fulcrum's sickle cell emergency access program?

Fulcrum's commitment supports a three-year partnership launched March 19, 2026 to broaden reach and accelerate ED access to care plans. According to Fulcrum, the collaboration builds on a program originally started in 2023 and aims to expand enrollment across the SCD community.

Will the MedicAlert digital profiles include physician-approved sickle cell pain plans and clinician contact details?

Yes, the digital profiles include physician-approved sickle cell pain plans and hematologist contact information accessible via the card QR code. According to MedicAlert, profiles also display medications, allergies, and other essential health information to support emergency clinicians.